Quality Improvement in Gastroenterology Clinical Practice

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 12, 2012, Pages 1305-1314

  Kheraj, Rakhi ^a   Tewani, Sumeet K ^a   Ketwaroo, Gyanprakash ^a   Leffler, Daniel A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Celiac Disease; Improvement; Inflammatory Bowel Disease; Liver Disease; Quality

Indexed keywords

ALPHA FETOPROTEIN; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE;

ACCREDITATION; BARRETT ESOPHAGUS; BONE DENSITY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CELIAC DISEASE; CERTIFICATION; CHROMOENDOSCOPY; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC MUCOSAL RESECTION; ENTERITIS; ESOPHAGUS RESECTION; ESOPHAGUS VARICES; EVIDENCE BASED PRACTICE; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DYSPLASIA; HEALTH CARE COST; HEALTH CARE QUALITY; HEPATITIS B VIRUS; HUMAN; IRRITABLE COLON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG TUBERCULOSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT CARE; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; REVIEW; TOTAL QUALITY MANAGEMENT; ULCERATIVE COLITIS; VACCINATION; VIRUS LOAD;

CHRONIC DISEASE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASES; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; QUALITY IMPROVEMENT;

EID: 84869448743     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.08.004     Document Type: Review

References (92)

1. Hudson P. Applying the lessons of high risk industries to health care. Qual Saf Health Care 2003, 12(Suppl 1):i7-i12.
2. Cleghorn G.D., Headrick L.A. The PDSA cycle at the core of learning in health professions education. Jt Comm J Qual Improv 1996, 22:206-212.
3. Guinane C.S., Sikes J.I., Wilson R.K. Using the PDSA cycle to standardize a quality assurance program in a quality improvement-driven environment. Jt Comm J Qual Improv 1994, 20:696-705.
4. Rex D.K., Petrini J.L., Baron T.H., et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006, 101:873-885.
5. Ward S.H., Lin K., Meyer B., et al. Increasing colorectal cancer screening among African Americans, linking risk perception to interventions targeting patients, communities and clinicians. J Natl Med Assoc 2008, 100:748-758.
6. Christie J., Itzkowitz S., Lihau-Nkanza I., et al. A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities. J Natl Med Assoc 2008, 100:278-284.
7. Rawl S.M., Champion V.L., Scott L.L., et al. A randomized trial of two print interventions to increase colon cancer screening among first-degree relatives. Patient Educ Couns 2008, 71:215-227.
8. Friedman M., Borum M.L. Colorectal cancer screening of African Americans by internal medicine resident physicians can be improved with focused educational efforts. J Natl Med Assoc 2007, 99:1010-1012.
9. Khankari K., Eder M., Osborn C.Y., et al. Improving colorectal cancer screening among the medically underserved: a pilot study within a federally qualified health center. J Gen Intern Med 2007, 22:1410-1414.
10. Guerra C.E., Schwartz J.S., Armstrong K., et al. Barriers of and facilitators to physician recommendation of colorectal cancer screening. J Gen Intern Med 2007, 22:1681-1688.
11. Shaw M.J., Beebe T.J., Tomshine P.A., et al. A randomized, controlled trial of interactive, multimedia software for patient colonoscopy education. J Clin Gastroenterol 2001, 32:142-147.
12. Leffler D.A., Neeman N., Rabb J.M., et al. An alerting system improves adherence to follow-up recommendations from colonoscopy examinations. Gastroenterology 2011, 140:1166-1173.
13. Siddiqui A.A., Yang K., Spechler S.J., et al. Duration of the interval between the completion of bowel preparation and the start of colonoscopy predicts bowel-preparation quality. Gastrointest Endosc 2009, 69(Suppl):700-706.
14. Ko H.H., Zhang H., Telford J.J., et al. Factors influencing patient satisfaction when undergoing endoscopic procedures. Gastrointest Endosc 2009, 69:883-891.
15. Chung Y.W., Han D.S., Yoo K.S., et al. Patient factors predictive of pain and difficulty during sedation-free colonoscopy: a prospective study in Korea. Dig Liver Dis 2007, 39:872-876.
16. Lee A., Iskander J.M., Gupta N., et al. Queue position in the endoscopic schedule impacts effectiveness of colonoscopy. Am J Gastroenterol 2011, 106:1457-1465.
17. Sanaka M.R., Deepinder F., Thota P.N., et al. Adenomas are detected more often in morning than in afternoon colonoscopy. Am J Gastroenterol 2009, 104:1659-1665.
18. Kottachchi D., Yung D., Marshall J.K. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol 2009, 23:613-617.
19. Rodriguez S.A., Collins J.M., Knigge K.L., et al. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc 2007, 65:432-439.
20. Lebwohl B., Kapel R.C., Neugut A.I., et al. Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointest Endosc 2011, 74:103-109.
21. Lieberman D., Nadel M., Smith R.A., et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007, 65:757-766.
22. Sawhney M.S., Salfiti N., Nelson D.B., et al. Risk factors for severe delayed postpolypectomy bleeding. Endoscopy 2008, 40:115-119.
23. Leffler D.A., Kheraj R., Garud S., et al. The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy. Arch Intern Med 2010, 170:1752-1757.
24. Dorn S.D. Gastroenterology in a new era of accountability: part 1-an overview of performance measurement. Clin Gastroenterol Hepatol 2011, 9:750-753.
25. Heathcote E.J. Management of primary biliary cirrhosis: the American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000, 31:1005-1013.
26. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
27. Kornbluth A., Hayes M., Feldman S., et al. Do guidelines matter?. Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006, 101:1546-1550.
28. Etzel J.P., Larson M.F., Anawalt B.D., et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 2011, 17:2122-2129.
29. Ferkolj I. How to improve the safety of biologic therapy in Crohn's disease. J Physiol Pharmacol 2009, 60(Suppl 7):67-70.
30. Melmed G.Y., Ippoliti A.F., Papadakis K.A., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101:1834-1840.
31. Wasan S.K., Baker S.E., Skolnik P.R., et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010, 105:1231-1238.
32. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011 Centers for Disease Control and Prevention, Accessed April 1, 2012. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm?s_cid=rr6002a1_e.
33. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
34. Farraye F.A., Odze R.D., Eaden J., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:738-745.
35. Collins P.D., Mpofu C., Watson A.J., et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006, 2. CD000279.
36. Itzkowitz S.H., Present D.H. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:314-321.
37. Ullman T.A. Colonoscopic surveillance in inflammatory bowel disease. Curr Opin Gastroenterol 2005, 21:585-588.
38. Farraye F.A., Odze R.D., Eaden J., et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:746-774.
39. Shale M.J., Seow C.H., Coffin C.S., et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
40. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
41. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-524.
42. Vaughn B.P., Doherty G.A., Gautam S., et al. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012, 18:1057-1063.
43. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935-939.
44. Brandt L.J., Chey W.D., et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35. American College of Gastroenterology Task Force on Irritable Bowel Syndrome.
45. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58:130-160.
46. Stebbing J.F. Quality assurance of endoscopy units. Best Pract Res Clin Gastroenterol 2011, 25:361-370.
47. Faigel D.O., Pike I.M., Baron T.H., et al. Quality indicators for gastrointestinal endoscopic procedures: an introduction. Am J Gastroenterol 2006, 101:866-872.
48. Petersen B.T. Quality assurance for endoscopists. Best Pract Res Clin Gastroenterol 2011, 25:349-360.
49. Vital signs: colorectal cancer screening among adults aged 50-75 years-United States 2008. MMWR Morb Mortal Wkly Rep 2010, 59:808-812.
50. Sint Nicolaas J., de Jonge V., Cahen D.L., et al. Awareness of surveillance recommendations among patients with colorectal adenomas. Clin Gastroenterol Hepatol 2012, 10:405-411.
51. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-1595.
52. Schoen R.E., Pinsky P.F., Weissfeld J.L., et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology 2010, 138:73-81.
53. Laiyemo A.O., Pinsky P.F., Marcus P.M., et al. Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial. Clin Gastroenterol Hepatol 2009, 7:562-567.
54. DeVault K.R., Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200. American College of Gastroenterology.
55. ICSI health care guideline: initial management of dyspepsia and GERD, 2006, Accessed April 1, 2012. http://www.icsi.org/dyspepsia_gerd/dyspepsia__9.html.
56. Gastroesophageal reflux disease (GERD) physician performance measurement set, 2007 GERD Work Group, Accessed April 1, 2012. http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/gerdws122107.pdf.
57. Lichtenstein D.R., Cash B.D., et al. Role of endoscopy in the management of GERD. Gastrointest Endosc 2007, 66:219-224. Standards of Practice Committee.
58. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1383-1391.
59. Spechler S.J., Sharma P., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091. American Gastroenterological Association.
60. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
61. Herzig S.J., Howell M.D., Ngo L.H., et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009, 301:2120-2128.
62. Hauben M., Horn S., Reich L., et al. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. Int J Infect Dis 2007, 11:417-422.
63. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
64. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
65. Alkhatib A.A., Elkhatib F.A., Khatib O.F. Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?. Am J Gastroenterol 2010, 105:1211.
66. Johnson C.E., Freel C.D., Kornbluth S. Features of programmed cell death in intact Xenopus oocytes and early embryos revealed by near-infrared fluorescence and real-time monitoring. Cell Death Differ 2010, 17:170-179.
67. Spechler S.J., Fitzgerald R.C., Prasad G.A., et al. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010, 138:854-869.
68. Hirota W.K., Zuckerman M.J., Adler D.G., et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006, 63:570-580.
69. Lekakos L., Karidis N.P., Dimitroulis D., et al. Barrett's esophagus with high-grade dysplasia: focus on current treatment options. World J Gastroenterol 2011, 17:4174-4183.
70. Lai M., Afdhal N.H. Health care quality measurement in the care of patients with cirrhosis. Clin Gastroenterol Hepatol 2010, 8:649-650.
71. Kanwal F., Kramer J., Asch S.M., et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol 2010, 8:709-717.
72. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
73. Franceschi S., Raza S.A. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009, 286:5-8.
74. Wong G.L., Wong V.W., Tan G.M., et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008, 28:79-87.
75. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. American Association for the Study of Liver Diseases.
76. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
77. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
78. Davila J.A., Morgan R.O., Richardson P.A., et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010, 52:132-141.
79. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
80. Groszmann R.J., Garcia-Tsao G., Bosch J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005, 353:2254-2261.
81. Merli M., Nicolini G., Angeloni S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003, 38:266-272.
82. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007, 102:2086-2102.
83. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010, 362:823-832.
84. D'Amico G., Pagliaro L., Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999, 19:475-505.
85. Saab S., DeRosa V., Nieto J., et al. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol 2003, 98:763-770.
86. Teran J.C., Imperiale T.F., Mullen K.D., et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 1997, 112:473-482.
87. Moodley J., Lopez R., Carey W. Compliance with practice guidelines and risk of a first esophageal variceal hemorrhage in patients with cirrhosis. Clin Gastroenterol Hepatol 2010, 8:703-708.
88. Leffler D. Celiac disease diagnosis and management: a 46-year-old woman with anemia. JAMA 2011, 306:1582-1592.
89. Evans K.E., Aziz I., Cross S.S., et al. A prospective study of duodenal bulb biopsy in newly diagnosed and established adult celiac disease. Am J Gastroenterol 2011, 106:1837-1842.
90. Elli L., Bardella M.T. Duodenal bulb biopsies and celiac disease. Gastrointest Endosc 2011, 73:1069.
91. Gee A. Concerns raised over new US resident physician work hours. Lancet 2011, 378:758.
92. Horwitz L.I. Why have working hour restrictions apparently not improved patient safety?. BMJ 2011, 342:d1200.